Ramakrishnan TCR, et al. - Researchers compared the efficacy and safety of tenecteplase (TNK-tPA), a promising third-generation plasminogen activator, with alteplase in patients with acute ischemic stroke by conducting two studies. The first was an open-label, randomized study in which two doses of TNK-tPA (0.1 and 0.2 mg/kg) were compared (Study I) and Study II which was an open-label study in which TNK-tPA 0.2 mg/kg bolus was compared with historical controls. Based on the findings, intravenous TNK-tPA 0.2 mg/kg seemed to have good tolerability as well as efficacy as a treatment option in patients with acute ischemic stroke when administered within 3 hours of symptom onset.